Prostate-specific antigen levels in relation to cadmium exposure and zinc intake: Results from the 2001-2002 National Health and Nutrition Examination Survey

Prostate

Volumn 68, Issue 2, 2008, Pages 122-128

  Van Wijngaarden, Edwin ^a   Singer, Eric A ^a   Palapattu, Ganesh S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cadmium; Epidemiology; Prostate specific antigen; Zinc

Indexed keywords

CADMIUM; PROSTATE SPECIFIC ANTIGEN; ZINC;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENICITY; CORRELATION ANALYSIS; DIETARY INTAKE; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; EXPERIMENTAL STUDY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; ORGANIZATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RISK FACTOR; SCHOOL CHILD; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CADMIUM; DIETARY SUPPLEMENTS; ENVIRONMENTAL EXPOSURE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ZINC;

EID: 38749132342     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20668     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101 (10 Suppl):2371-2490.
3. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003;30(2):209-217.
4. Gallagher RP, Fleshner N. Prostate cancer. 3. Individual risk factors. CMAJ 1998;159(7):807-813.
5. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(9360):859-864.
6. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 2001;23(1):3-13.
7. Levy IG, Iscoe NA, Klotz LH. Prostate cancer. 1. The descriptive epidemiology in Canada. CMAJ 1998;159(5):509-513.
8. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: Epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005;80(7):899-907.
9. Signorello LB, Adami HO. Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. New York, NY: Oxford University Press; 2002. pp 400-428.
10. Stotts RC. Cancers of the prostate, penis, and testicles: Epidemiology, prevention, and treatment. Nurs Clin North Am 2004;39(2):327-340.
11. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-1413.
12. Parent ME, Siemiatycki J. Occupation and prostate cancer. Epidemiol Rev 2001;23(1):138-143.
13. Pinot F, Kreps SE, Bachelet M, Hainaut P, Bakonyi M, Polla BS. Cadmium in the environment: Sources, mechanisms of biotoxicity, and biomarkers. Rev Environ Health 2000;15(3):299-323.
14. Satarug S, Baker JR, Reilly PE, Moore MR, Williams DJ. Cadmium levels in the lung, liver, kidney cortex, and urine samples from Australians without occupational exposure to metals. Arch Environ Health 2002;57(1):69-77.
15. Satarug S, Moore MR. Adverse health effects of chronic exposure to low-level cadmium in foodstuffs and cigarette smoke. Environ Health Perspect 2004;112(10):1099-1103.
16. Wittman R, Hu H. Cadmium exposure and nephropathy in a 28-year-old female metals worker. Environ Health Perspect 2002;110(12):1261-1266.
17. National Center for Environmental Health. Third National Report on Human Exposure to Environmental Chemicals. Atlanta, GA: National Center for Environmental Health, Division of Laboratory Sciences; Centers for Disease Control and Prevention, Department of Health and Human Services; 2005. Report nr NCEH Pub. No.05-0570. pp 26-30.
18. Kazantzis G. Cadmium, osteoporosis and calcium metabolism. Biometals 2004;17(5):493-498.
19. Jarup L, Berglund M, Elinder CG, Nordberg G, Vahter M. Health effects of cadmium exposure - A review of the literature and a risk estimate. Scand J Work Environ Health 1998;24 (Suppl 1):1-51.
20. Satarug S, Baker JR, Urbenjapol S, Haswell-Elkins M, Reilly PE, Williams DJ, Moore MR. A global perspective on cadmium pollution and toxicity in non-occupationally exposed population. Toxicol Lett 2003;137(1-2):65-83.
21. Verougstraete V, Lison D, Hotz P. Cadmium, lung and prostate cancer: A systematic review of recent epidemiological data. J Toxicol Environ Health B Crit Rev 2003;6(3):227-255.
22. Yassin AS, Martonik JF. Urinary cadmium levels in the U S working population, 1988-1994. J Occup Environ Hyg 2004;1(5):324-333.
23. Sahmoun AE, Case LD, Jackson SA, Schwartz GG. Cadmium and prostate cancer: A critical epidemiologic analysis. Cancer Invest 2005;23(3):256-263.
24. Paschal DC, Burt V, Caudill SP, Gunter EW, Pirkle JL, Sampson EJ, Miller DT, Jackson RJ. Exposure of the U.S. population aged 6 years and older to cadmium: 1988-1994. Arch Environ Contam Toxicol 2000;38(3):377-383.
25. Jarup L. Cadmium overload and toxicity. Nephrol Dial Transplant 2002;17 (Suppl 2):35-39.
26. Potts CL. Cadmium Proteinuria - The Health of Battery Workers Exposed to Cadmium Oxide Dust. Ann Occup Hyg 1965;10:55-61.
27. Waalkes MP. Cadmium carcinogenesis in review. J Inorg Biochem 2000;79(1-4):241-244.
28. Waalkes MP. Cadmium carcinogenesis. Mutat Res 2003;533 (1-2):107-120.
29. Goyer RA, Liu J, Waalkes MP. Cadmium and cancer of prostate and testis. Biometals 2004;17(5):555-558.
30. Ye J, Wang S, Barger M, Castranova V, Shi X. Activation of androgen response element by cadmium: A potential mechanism for a carcinogenic effect of cadmium in the prostate. J Environ Pathol Toxicol Oncol 2000;19(3):275-280.
31. NCHS. NHANES 2001-2002 Data Files. Vol. 2005. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2005.
32. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 2005;97(15):1132-1137.
33. Saraiya M, Kottiri BJ, Leadbetter S, Blackman D, Thompson T, McKenna MT, Stallings FL. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev 2005;14(9):2178-2182.
34. Zeng X, Jin T, Jiang X, Kong Q, Ye T, Nordberg GF. Effects on the prostate of environmental cadmium exposure - A cross-sectional population study in China. Biometals 2004;17(5):559-565.
35. Zeng X, Jin T, Zhou Y, Nordberg GF. Changes of serum sex hormone levels and MT mRNA expression in rats orally exposed to cadmium. Toxicology 2003;186(1-2):109-118.
36. Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, Srivastava S, Rhim JS. Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol 2002;20(3):543-547.
37. Brys M, Nawrocka AD, Miekos E, Zydek C, Foksinski M, Barecki A, Krajewska WM. Zinc and cadmium analysis in human prostate neoplasms. Biol Trace Elem Res 1997;59(1-3):145-152.
38. Achanzar WE, Webber MM, Waalkes MP. Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate 2002;52(3):236-244.
39. Hartwig A. Carcinogenicity of metal compounds: Possible role of DNA repair inhibition. Toxicol Lett 1998;102-103:235-239.
40. Abshire MK, Buzard GS, Shiraishi N, Waalkes MP. Induction of c-myc and c-jun proto-oncogene expression in rat L6 myoblasts by cadmium is inhibited by zinc preinduction of the metallothionein gene. J Toxicol Environ Health 1996;48(4):359-377.
41. Elghany NA, Schumacher MC, Slattery ML, West DW, Lee JS. Occupation, cadmium exposure, and prostate cancer. Epidemiology 1990;1(2):107-115.
42. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer 2006;5:17.
43. Platz EA, Helzlsouer KJ, Hoffman SC, Morris JS, Baskett CK, Comstock GW. Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk. Prostate 2002;52(4):288-296.
44. van der Gulden JW, Kolk JJ, Verbeek AL. Work environment and prostate cancer risk. Prostate 1995;27(5):250-257.
45. Vinceti M, Venturelli M, Sighinolfi C, Trerotoli P, Bonvicini F, Ferrari A, Bianchi G, Serio G, Bergomi M, Vivoli G. Case-control study of toenail cadmium and prostate cancer risk in Italy. Sci Total Environ 2007;373(1):77-81.
46. Gray MA, Centeno JA, Slaney DP, Ejnik JW, Todorov T, Nacey JN. Environmental exposure to trace elements and prostate cancer in three New Zealand ethnic groups. Int J Environ Res Public Health 2005;2(3-4):374-384.
47. Meyer F, Fradet Y. Prostate cancer. 4. Screening. CMAJ 1998;159(8):968-972.
48. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB. Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA 2003;289(20):2695-2700.
49. Troyer DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 2004;20(2):117-128.
50. Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. Urology 2005;66(4):803-807.
51. Boyle P. Screening for prostate cancer: Have you had your cholesterol measured? BJU Int 2003;92(3):191-199.
52. Harris R, Lohr KN. Screening for prostate cancer: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137(11):917-929.
53. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98(8):529-534.